After Hours Decliner
PRAX Praxis Precision Medicines350.56+22.77+7.0%
After Hours:330.00-20.56 (-5.9%)
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Globe NewswireMon, 29-Jun 4:30 PM
PRAX Praxis Precision Medicines256.28+66.31 (+34.9%)
After Hours Gainer
PRAX Praxis Precision Medicines189.97+3.82+2.1%
After Hours:208.00+18.03 (+9.5%)
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Globe NewswireThu, 4-Dec 4:10 PM
PRAX Praxis Precision Medicines166.42-5.93 (-3.4%)
PRAX Praxis Precision Medicines161.68-10.07 (-5.9%)
PRAX Praxis Precision Medicines173.24-25.52 (-12.8%)